Generated by AI
Neuphoria Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for neuropsychiatric and central nervous system disorders. The company’s current pipeline centers on BNC210, an oral drug candidate being developed for social anxiety disorder and post-traumatic stress disorder, with a mechanism designed to selectively modulate the a7 nicotinic acetylcholine receptor. Neuphoria Therapeutics also works on other preclinical and clinical programs in neuroscience and oncology, reflecting a research-driven portfolio that spans multiple therapeutic areas. Headquartered in Burlington, Massachusetts, with operations connected to Australia, the company contributes to the broader biopharmaceutical market by advancing drug candidates aimed at complex neurological and psychiatric conditions.
Website14 Milliston Road
Millis, MA, 02054
United States
The latest articles about NEUP.
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF, FRA:SCP), the developer of cancer immunotherapies, is pressing ahead with plans to list on the Nasdaq stock exchange following an all-share merger with US biotech Neuphoria Therapeutics, announced in July. The combined company will trade under the...
Summary of Jul 23's posts. Generated by AI.
Summary of Oct 27's posts. Generated by AI.
Summary of Jul 23's posts. Generated by AI.
Investors talking about NEUP also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.